Good for you. Glad to see you took advantage of this insane low price.
You worked in a big company before you retired. You know how those big companies would act when they spot a great opportunity.
We all know how CSF1R-I is essential in dealing with immuno-suppressive microenvironment. Today, out of curiosity, I checked out which companies were trying to develop CSF1R-I. I made my predictions even before I did the search that Merck or BPs would form a partnership with any company which had preliminary positive results. Here is what I found for a company from South Korea which is trying to develop triple inhibitors including CSF1R.
Qurient has the technology for the orally available immuno-oncology therapeutic small molecule, targeting selectively Axl, Mer, and CSF1R, originated from the Max Planck Institute of Biochemistry.
The small molecule drug called Q702 is an orally available, selective Axl/Mer/CSF1R triple kinase inhibitor showing significant in vivo activity as monotherapy as well as in combination with anti-PD-1 antibody. Q702 not only modulates innate immune components such as myeloid derived suppressor cell, tumor associated macrophage in tumor micro-environment, but also increases MHC I expression in tumor cell.
Would Merck be interested in anything that can take care of immunosuppressive characteristic resulting from tumor-associated macrophage? Absolutely!
Then I thought myself that's really interesting. I went to check Amgen. Here is what I found.
It is interesting to see that in collaboration with LifeMax Laboratories, Amgen is trying to develop CSF1R-I by forming a joint venture called AmMaxBio. And the more interesting part is that Amgen just started the p3 trial on Keytruda biosimilar. The combination of this two with the platform from NWBO is the way to cure cancer!
It won't be lone now. I put several weeks ago at 47 cents and then again a few weeks later at 45 cents. I didn't by on this last dip Friday. I have several thousand shares many of which I bought at around 20 cents so got a good amount already. I agree with you that if you need the money it is one thing but if the money is strictly an investment that's another. When one considers risk vs potential reward where do you get a better investment than NWBO. It won't be long now. Even if we go up to $3 or $10 on approval in England for GBM I believe this is still a really good longer term investment when this gets WW approval for all solid tumor cancers and DCVAX Direct for inoperable solid tumors. Just look at the revenue potential when this become Standard of Care GLTU.